ActiveMax® Recombinant Mouse VEGF120 Protein, Tag Free, 20 µg

Background
Vascular endothelial growth factor A (VEGFA) is also known as Vascular permeability factor (VPF). VEGFA belongs to the PDGF/VEGF growth factor family. VEGFA is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. VEGFA is produced by a group of three major isoforms as a result of alternative splicing and if any three isoforms are produced (VEGFA120, VEGFA164, and VEGFA188) then this will not result in vessel defects and death of the full VEGFA knockout in mice.

Source
ActiveMax® Recombinant Mouse VEGF120, Tag Free (VE0-M4211) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 146 (Accession # AAB22254.1 ).
Predicted N-terminus: Ala 27

Molecular Characterization
This protein carries no "tag". The protein has a calculated MW of 14.1 kDa. The protein migrates as 18-22 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 0.1 EU per μg by the LAL method.

Sterility
The sterility testing was performed by membrane filtration method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Investigation of the mechanisms of VEGF-mediated compensatory lung growth: the role of the VEGF heparin-binding domain"
Yu, Ko, Dao et al
Sci Rep (2021) 11 (1), 11827
(2) "Hypoxia up-regulates VEGF ligand and downregulates VEGF soluble receptor mRNA expression in bovine granulosa cells in vitro"
Hernández-Morales, Hernández-Coronado, Guzmán et al
Theriogenology (2021) 165, 76-83
(3) "Pulmonary ductal coarctation and left pulmonary artery interruption; pathology and role of neural crest and second heart field during development"
Gittenberger-de Groot, Peterson, Wisse et al
PLoS One (2020) 15 (5), e0228478
Showing 1-3 of 159 papers.